6
Participants
Start Date
January 31, 2011
Primary Completion Date
July 31, 2016
Study Completion Date
October 31, 2016
Tasigna
Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated.
Riley Hospital for Children, Indianapolis
Collaborators (1)
Novartis
INDUSTRY
Indiana University
OTHER